Integrating concurrent navelbine and cisplatin to hyperfractionated radiotherapy in locally advanced non-small cell lung cancer patients treated with induction and consolidation chemotherapy: Feasibility and activity results

Lung Cancer

Volumn 45, Issue 1, 2004, Pages 67-75

  Reguart, N ^a   Vinolas N ^a   Casas, F ^a   Gimferrer, J M ^a   Agusti C ^a   Molina, R ^a   Martin Richard, M ^a   Sanchez Reyes, A ^a   Gascon P ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Advanced non small cell lung cancer; Chemotherapy; Concurrent radiotherapy; Hyperfractionation; Navelbine; Survival; Toxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DYSPNEA; ESOPHAGITIS; ESOPHAGUS STENOSIS; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NEUTROPENIA; PARALYTIC ILEUS; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RESPIRATORY FAILURE; SEPSIS; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TREATMENT OUTCOME; VINBLASTINE;

EID: 2942516071     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2003.12.012     Document Type: Article

References (35)

1. Dillman R.O., Herdon J., Seagren S.L., Eaton W.L. Jr., Green M.R. Improved survival in stage III non-small cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J. Natl. Cancer Inst. 88:1996;1210-1215
2. Le Chevalier T., Arriagada R., Quoix E., Ruffie P., Martin M., Tarayre M., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in non-resectable non-small cell lung cancer: first analysis of a randomized trial in 353 patients. J. Natl. Cancer Inst. 83:1991;417-423
3. Sause W.T., Kolesar P., Taylor S. IV, Johnson D., Livingston R., Komaki R., et al. Final results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer: radiation therapy oncology group, eastern cooperative oncology group, southwest oncology group. Chest. 117:2000;358-364
4. Mattson K., Holsti L.R., Holsti P., Jakobsson M., Kajanti M., Liippo K., et al. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur. J. Cancer Clin. Oncol. 24:1988;477-482
5. Morton R.F., Jett J.R., McGinnis W.L., Earle J.D., Therneau T.M., Krook J.E., et al. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann. Int. Med. 115:1991;681-686
6. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899-909.
7. Curran WJ, Scott C, Langer C, Komaki R, Lee J, Hauser S, et al. Phase III comparison of sequential vs. concurrent chemoradiation for PTS with unresected stage III non-small cell lung cancer (NSCLC): initial report of radiation therapy oncology group (RTOG 9410). Proc Am Soc Clin Oncol 2000;484a (Abstract 1891).
8. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine and cisplatin in unresectable stage III non-small-cell lung cancer (NSCLC). J. Clin. Oncol. 17:1999;2692-2699
9. Furuse K, Hosoe S, Masuda N, Sugiura T, Yokota S, Ohbayashi K, et al. Impact of tumor control on survival in unresectable stage III non-small-cell lung cancer (NSCLC) treated with concurrent thoracic radiotherapy (TRT) and chemotherapy. Proc Am Soc Clin Oncol 2000;484a (Abstract 1893).
10. Zatloukal PV, Petruzelka L, Zemanova M, Havel L, Pecen L, Krepela E, et al. Concurrent versus sequential radiochemotherapy with vinorelbine plus cisplatin (V-P) in locally advanced non-small-cell lung cancer. A randomized phase II study. Proc Am Soc Clin Oncol 2002;290a (Abstract 1159).
11. Belani C.P., Ramanathan R.K. Combined-modality treatment of locally advanced non-small lung cancer: incorporation of novel chemotherapeutic agents. Chest. 113(Suppl. 1):1998;53S-60S
12. Choy H., LaPorte K., Knill-Selby E., Mohr P., Shyr Y. Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin. Radiat. Oncol. 9(2 Suppl. 1):1999;90-96
13. Gallardo D, Calderillo G, Alcedo J, Martinez L, Green L, Zamora J, et al. Long term survival with cisplatin and vinorelbine plus radiotherapy in unresectable non-small cell lung cancer. Phase II study. Proc Am Soc Clin Oncol 2001;262b (Abstract 2798).
14. Jeremic B, Shibamoto Y, Acimovic L, Milicic B, Milisavljevic S, Nikolic, et al. Hyperfractionated radiation therapy and concurrent low-dose daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial. Int. J Radiat Oncol Biol Phys 2001;50(1):19-25.
15. Cox J.D., Azarnia N., Byhardt R.W., Shin K.H., Emami B., Pajak T.F. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with radiation therapy oncology group stage III non-small-cell lung carcinoma: report of radiation therapy oncology group 83-11. J. Clin. Oncol. 8(9):1990;1543-1555
16. Uitterhoeve A.L., Belderbos J.S., Koolen M.G., Van Der Vaart P.J., Rodrigus P.T., Benraadt J., et al. Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. European organization for research and treatment of cancer. Eur. J. Cancer. 36(5):2000;592-600
17. Sun L.M., Leung S.W., Wang C.J., Chen H.C., Fang F.M., Huang E.Y., et al. Concomitant boost radiation therapy for inoperable non-small-cell lung cancer: preliminary report of a prospective randomized study. Int. J. Radiat. Oncol. Biol. Phys. 47(2):2000;413-418
18. International Commission on Radiation Units and Measurements. ICRU Report No. 50: prescribing, recording, and reporting photon beam therapy. Bethesda, MD: International Commission on Radiation Units and Measurements, 1993.
19. International Commission on Radiation Units and Measurements. ICRU Report No. 62: prescribing, recording, and reporting photon beam therapy (supplement to ICRU Report No. 50). Bethesda, MD: International Commission on Radiation Units and Measurements, 1999.
20. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 47(1):1981;207-214
21. Albain K.S., Crowley J.J., Turrisi A.T. III, Gandara D.R., Farrar W.B., Clark J.I., et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a southwest oncology group phase II study, SWOG 9019. J. Clin. Oncol. 20(16):2002;3454-3460
22. Byhardt R.W., Scott C., Sause W.T., Emami B., Komaki R., Fisher B., et al. Response, toxicity, failure patterns, and survival in five radiation therapy oncology group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int. J. Radiat. Oncol. Biol. Phys. 42(3):1998;469-478
23. Schaake-Koning C., Van den Bogaert W., Dalesio O., Festen J., Hoogenhout J., Van Houtte P., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N. Engl. J. Med. 326(8):1992;524-530
24. Jeremic B., Shibamoto Y., Acimovic L., Milisavljevic S. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage II non-small-cell lung cancer: a randomized study. J. Clin. Oncol. 14(4):1996;1065-1070
25. Choy H., Devore R.F. III, Hande K.R., Porter L.L., Rosenblatt P., Yunus F., et al. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt cancer center affiliate network study). Int. J. Radiat. Oncol. Biol. Phys. 47(4):2000;931-937
26. Giaccone G., Splinter T.A., Debruyne C., Kho G.S., Lianes P., Van Zandwijk N., et al. Randomized study of paclitaxel-cisplatin vs cisplatin-teniposide in patients with advanced non-small cell lung cancer. J. Clin. Oncol. 16:1998;2133-2141
27. Cardenal F., Lopez-Cabrerizo M.P., Anton A., Alberola V., Massuti B., Carrato A., et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. 17:1999;12-18
28. Le Chevalier T., Brisgand D., Douillard J.Y., Pujol J.L., Alverola V., Monnier A., et al. Randomized study of vinorelbine and cisplatin versus vinorelbine alone versus vindesine and cisplatin in advanced non-small cell lung cancer. Results of a European multicenter trial including 612 patients. J. Clin. Oncol. 12:1994;360-367
29. Scalliet P, Goor C, Galdermans D, Van Meerbeek J, Groen HJM, Van der Leest AHD, et al. Gemcitabine with thoracic radiotherapy - a phase II pilot study in chemonaive patients with advanced non-small-cell lung cancer. Proc Am Soc Clin Oncol 1998;499a (Abstract 1923).
30. Trodella L., Granone P., Valente S., Valentini V., Balducci M., Mantini G., et al. Phase I trial of weekly gemcitabine ad concurrent radiotherapy patients with inoperable non-small-cell lung cancer. J. Clin. Oncol. 20(3):2002;804-810
31. Choy H, DeVore RD, Akerley W, Safran H, Graziano S, Williams T, et al. Sequential phase II studies of paclitaxel +/- carboplatin and radiation therapy (+/- hyperfractionation HFXRT) for locally advanced non-small-cell lung cancer (NSCLC): multi-institutional trials. Proc Am Soc Clin Oncol 2000;499a (Abstract 1951).
32. Vokes E.E., Herndon J.E. II, Crawford J., Leopold K.A., Perry M.C., Miller A.A. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB. Non-small-cell lung cancer: cancer and leukemia group study 9431. J. Clin. Oncol. 20(20):2002;4191-4198
33. Brechot J.M., Chvret S., Nataf J., Le Gall C., Fretault J., Rochemaure J., et al. Diagnostic and prognostic value of Cyfra 21.1 compared with other tumor markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur. J. Cancer. 33:1997;385-391
34. Ray P., Quantin X., Grenier J., Pujol J.L. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. Cancer Detect. Prev. 22:1998;293-304
35. Vinolas N., Molina R., Galan M.C., Casas F., Callejas M.A., Filella X., et al. Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report. Anticancer Res. 18:1998;631-634